Related Experiment Videos
Personalized one-two punches for lung cancer
Hannah A Scarborough1, Paul A Bunn2, James DeGregori3
11] Program in Molecular Biology, University of Colorado Cancer Center, Aurora, CO 80045, USA [2] Department of Biochemistry and Molecular Genetics, University of Colorado Cancer Center, Aurora, CO 80045, USA.
Cell Research
|December 31, 2014
Summary
Researchers developed a new method to test drug combinations on patient cancer cells, overcoming challenges in developing personalized therapies for tyrosine kinase inhibitor (TKI) resistance.
Area of Science:
- Oncology
- Pharmacology
- Biotechnology
Background:
- Developing individualized therapies for tyrosine kinase inhibitor (TKI) resistance remains a significant challenge.
- The inability to test drug combinations on patient-derived samples hinders progress in overcoming TKI resistance.
Purpose of the Study:
- To establish a novel methodology for pharmacological screening.
- To enable the testing of drug combinations on patient samples before and after TKI resistance.
Main Methods:
- Utilized a panel of 76 targeted agents for screening.
- Employed cell lines derived directly from patient biopsies.
- Developed a method for pharmacological screening of drug combinations.
Main Results:
- Successfully created a system for testing drug combinations on patient-derived cell lines.
- The methodology allows for screening before and after the development of TKI resistance.
- Facilitates the discovery of potential therapeutic strategies against TKI resistance.
Conclusions:
- The described methodology provides a powerful tool for advancing personalized cancer therapy.
- Enables the identification of effective drug combinations to overcome TKI resistance.
- Offers a pathway to address a critical unmet need in oncology treatment.